Abstract
Scleroderma (SSc) is a multisystem disorder characterized by fibrosis and collagen deposition in the dermis, but affects multiple organ systems, leading to esophageal dysmotility, renal failure, and interstitial lung disease (ILD). ILD is common manifestation of diffuse type of SSc and may be life threatening, and require aggressive therapy with cytotoxic agents. Although high-dose steroid and cyclophosphamide are most commonly used therapy for SSc-associated ILD, the efficacy is questionable in some cases and more effective and less toxic therapies are needed. Rituximab (RTX) is a chimeric mAb against human CD20 that depletes peripheral B cells and introduced for systemic rheumatic diseases. However, there were no enough evidences for SSc-associated ILD. We report herein a case of 47-year-old female with diffuse type of SSc with steroid and cyclophosphamide-resistant ILD that was successfully treated with RTX. Thus, we suggested that RTX could be an efficacious therapeutic modality for severe, conventional treatment-resistant SSc-associated ILD.
References
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666
Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970
Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27(4):357–361
Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17(6):746–751
Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41(12):1123–1133
Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169(3):954–966
Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, de Keyser F (2008) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (epub ahead of print)
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60(2):578–583
McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47(4):552–553
Steen V (2004) Changes in causes of death in SSc over the past 30 years. Arthritis Rheum 50(S9)(Abstract 1052):S422
Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr (1985) Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 28(7):759–767
Maas D, Schramm A, Jackle B, Raif W, Schubothe H (1979) Progressive systemic sclerosis—long-term treatment with azathioprin (author’s transl). Immun Infekt 7(5):165–169
Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE (2006) Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 45(12):1572
Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50(6):1918–1927
Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100(21):12319–12324
Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56(9):3167–3168
Hasegawa M, Fujimoto M, Takehara K, Sato S (2005) Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39(1):1–7
Bosello S, De Santis M, Lama G (2007) Clinical improvement in systemic slerosis patients treated with anti-CD20. Arthritis Rheum Sup 56:S494
Lombardi S, Quartuccio L, Franzolini N (2008) Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Sup 58:S822–S823
Adams AB, Barillas-Arias L, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA (2006) Cyclophosphamide and rituximab combination therapy for the treatment of juvenile onset scleroderma: 6 Patient Case Series. In: Proceedings of ACR/ARHP annual scientific meeting 2006, Washington, DC, USA, pp 10–15
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoo, WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 32, 795–798 (2012). https://doi.org/10.1007/s00296-009-1347-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1347-z